Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Tg Therapeutics Inc's Business Segments
Tg Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
Product
Total Revenue
$ 205
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Product98.2%
- Product Neuraxpharm3.2%
- License Revenue1.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 201 | 98.2% |
| Product Neuraxpharm | $ 7 | 3.2% |
| License Revenue | $ 4 | 1.8% |
Revenue by Product & Service Category - FY
- Product98.2%
- License Revenue1.8%
- License1.8%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 201 | 98.2% |
| License Revenue | $ 4 | 1.8% |
| License | $ 4 | 1.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Product98.2%
- Product Neuraxpharm3.2%
- License Revenue1.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 201 | 98.2% |
| Product Neuraxpharm | $ 7 | 3.2% |
| License Revenue | $ 4 | 1.8% |
Description of Tg Therapeutics Inc
TG Therapeutics Inc. is a publicly-traded biopharmaceutical company based in New York City, focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. The company's pipeline consists of multiple product candidates, including small molecule inhibitors and monoclonal antibodies.
One of the company's most advanced product candidates is umbralisib, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase-1 epsilon (CK1ε) that is being evaluated in clinical trials for the treatment of hematologic malignancies and solid tumors. The drug has demonstrated promising anti-tumor activity in early-phase studies and is currently in phase III development for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
TG Therapeutics also has a pipeline of monoclonal antibodies targeting B-cell-specific proteins, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody that targets the same protein as rituximab but has greater efficacy and reduced side effects. This drug, in combination with umbralisib, has shown potential in a phase III clinical trial for relapsed or refractory CLL/SLL.
The company's other product candidates include TG-1501, a monoclonal antibody that targets a B-cell receptor signaling protein, and TG-1701, a next-generation BTK inhibitor that is in preclinical development.
TG Therapeutics is also exploring the potential of its product candidates in other indications, such as multiple sclerosis and inflammatory bowel disease.
In addition to its drug development efforts, TG Therapeutics has also entered into partnerships and collaborations with other companies, academic institutions, and research organizations to advance the development of its product candidates and expand its pipeline.
Overall, TG Therapeutics is a cutting-edge biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. With a strong pipeline of product candidates and ongoing clinical trials, the company has the potential to make a significant impact on patient outcomes in these therapeutic areas.
One of the company's most advanced product candidates is umbralisib, an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase-1 epsilon (CK1ε) that is being evaluated in clinical trials for the treatment of hematologic malignancies and solid tumors. The drug has demonstrated promising anti-tumor activity in early-phase studies and is currently in phase III development for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
TG Therapeutics also has a pipeline of monoclonal antibodies targeting B-cell-specific proteins, including ublituximab, a glycoengineered anti-CD20 monoclonal antibody that targets the same protein as rituximab but has greater efficacy and reduced side effects. This drug, in combination with umbralisib, has shown potential in a phase III clinical trial for relapsed or refractory CLL/SLL.
The company's other product candidates include TG-1501, a monoclonal antibody that targets a B-cell receptor signaling protein, and TG-1701, a next-generation BTK inhibitor that is in preclinical development.
TG Therapeutics is also exploring the potential of its product candidates in other indications, such as multiple sclerosis and inflammatory bowel disease.
In addition to its drug development efforts, TG Therapeutics has also entered into partnerships and collaborations with other companies, academic institutions, and research organizations to advance the development of its product candidates and expand its pipeline.
Overall, TG Therapeutics is a cutting-edge biopharmaceutical company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. With a strong pipeline of product candidates and ongoing clinical trials, the company has the potential to make a significant impact on patient outcomes in these therapeutic areas.
TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for cancer and autoimmune diseases. The companys extensive portfolio is divided into two primary segments: oncology and immunology. Each segment features a variety of advanced therapeutics designed to address unmet medical needs.
Oncology Segment
1. Umbralisib:
- Description: Umbralisib is an oral, once-daily next-generation phosphoinositide 3-kinase (PI3K) delta inhibitor.
- Indications: It is approved by the FDA for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL).
- Mechanism of Action: By selectively inhibiting PI3K delta, Umbralisib interferes with the signaling pathways that promote the growth and survival of malignant B-cells, leading to reduced tumor proliferation and enhanced apoptosis.
2. Ublituximab:
- Description: Ublituximab is a next-generation monoclonal antibody that targets the CD20 antigen on B-cells.
- Indications: This therapeutic is indicated for use in combination therapies for hematologic malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
- Mechanism of Action: Ublituximab kills B-cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), enhancing immune-mediated tumor destruction.
3. TG-1701:
- Description: TG-1701 is a highly selective, oral Brutons tyrosine kinase (BTK) inhibitor.
- Clinical Status: It is currently in Phase 1 clinical trials for various B-cell malignancies, including CLL and lymphoma.
- Mechanism of Action: TG-1701 aims to block BTK, a critical enzyme in B-cell receptor signaling, thereby inhibiting B-cell proliferation and survival.
4. TG-1801:
- Description: TG-1801 is a bispecific antibody designed to bind simultaneously to CD20 and CD4
- Development Focus: It is being developed for the treatment of B-cell malignancies, leveraging dual specificity to enhance therapeutic efficacy and overcome tumor evasion mechanisms.
Immunology Segment
1. Ublituximab (in immunology):
- Description: In addition to its oncology applications, Ublituximab is also being investigated for its role in treating autoimmune diseases.
- Indications: It shows promise in the treatment of multiple sclerosis (MS), lupus, and rheumatoid arthritis by targeting B-cells involved in autoimmune pathways.
2. TG-1501:
- Description: TG-1501 is a novel glycoengineered anti-CD19 antibody.
- Indications: It is under development for autoimmune diseases including MS, lupus, and neuromyelitis optica spectrum disorder (NMOSD).
- Mechanism of Action: By targeting CD19, TG-1501 can selectively deplete B-cells that contribute to autoimmune pathology while sparing healthy B-cells.
3. TG-1702:
- Description: TG-1702 is another highly selective, orally available BTK inhibitor.
- Clinical Status: Currently in Phase 1 trials targeted at autoimmune conditions, particularly MS and lupus.
- Mechanism of Action: Similar to TG-1701, it inhibits BTK to disrupt B-cell signaling and function, potentially leading to a reduction in autoantibody production.
4. TG-1802 (in immunology):
- Description: This is a bispecific antibody targeting both CD19 and CD47, targeting autoimmunity.
- Development Focus: TG-1802 aims to enhance therapeutic responses in autoimmune diseases by simultaneously depleting aberrant B-cells and promoting anti-tumor and anti-autoimmune activity.
Research and Development Focus
TG Therapeutics Inc. is committed to advancing its research and development efforts to discover innovative therapies that can transform patient outcomes in oncology and immunology. The company emphasizes a patient-centric approach, striving to provide effective, comprehensive treatment options and addressing significant unmet medical needs across both cancer and autoimmune disease landscapes. Through robust clinical trials and novel drug mechanisms, TG Therapeutics is positioned to pioneer future advancements in therapeutic interventions.
Oncology Segment
1. Umbralisib:
- Description: Umbralisib is an oral, once-daily next-generation phosphoinositide 3-kinase (PI3K) delta inhibitor.
- Indications: It is approved by the FDA for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL).
- Mechanism of Action: By selectively inhibiting PI3K delta, Umbralisib interferes with the signaling pathways that promote the growth and survival of malignant B-cells, leading to reduced tumor proliferation and enhanced apoptosis.
2. Ublituximab:
- Description: Ublituximab is a next-generation monoclonal antibody that targets the CD20 antigen on B-cells.
- Indications: This therapeutic is indicated for use in combination therapies for hematologic malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).
- Mechanism of Action: Ublituximab kills B-cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), enhancing immune-mediated tumor destruction.
3. TG-1701:
- Description: TG-1701 is a highly selective, oral Brutons tyrosine kinase (BTK) inhibitor.
- Clinical Status: It is currently in Phase 1 clinical trials for various B-cell malignancies, including CLL and lymphoma.
- Mechanism of Action: TG-1701 aims to block BTK, a critical enzyme in B-cell receptor signaling, thereby inhibiting B-cell proliferation and survival.
4. TG-1801:
- Description: TG-1801 is a bispecific antibody designed to bind simultaneously to CD20 and CD4
- Development Focus: It is being developed for the treatment of B-cell malignancies, leveraging dual specificity to enhance therapeutic efficacy and overcome tumor evasion mechanisms.
Immunology Segment
1. Ublituximab (in immunology):
- Description: In addition to its oncology applications, Ublituximab is also being investigated for its role in treating autoimmune diseases.
- Indications: It shows promise in the treatment of multiple sclerosis (MS), lupus, and rheumatoid arthritis by targeting B-cells involved in autoimmune pathways.
2. TG-1501:
- Description: TG-1501 is a novel glycoengineered anti-CD19 antibody.
- Indications: It is under development for autoimmune diseases including MS, lupus, and neuromyelitis optica spectrum disorder (NMOSD).
- Mechanism of Action: By targeting CD19, TG-1501 can selectively deplete B-cells that contribute to autoimmune pathology while sparing healthy B-cells.
3. TG-1702:
- Description: TG-1702 is another highly selective, orally available BTK inhibitor.
- Clinical Status: Currently in Phase 1 trials targeted at autoimmune conditions, particularly MS and lupus.
- Mechanism of Action: Similar to TG-1701, it inhibits BTK to disrupt B-cell signaling and function, potentially leading to a reduction in autoantibody production.
4. TG-1802 (in immunology):
- Description: This is a bispecific antibody targeting both CD19 and CD47, targeting autoimmunity.
- Development Focus: TG-1802 aims to enhance therapeutic responses in autoimmune diseases by simultaneously depleting aberrant B-cells and promoting anti-tumor and anti-autoimmune activity.
Research and Development Focus
TG Therapeutics Inc. is committed to advancing its research and development efforts to discover innovative therapies that can transform patient outcomes in oncology and immunology. The company emphasizes a patient-centric approach, striving to provide effective, comprehensive treatment options and addressing significant unmet medical needs across both cancer and autoimmune disease landscapes. Through robust clinical trials and novel drug mechanisms, TG Therapeutics is positioned to pioneer future advancements in therapeutic interventions.